Biogen

Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors

Retrieved on: 
Thursday, February 15, 2024
Biotechnology, Health, Science, Pharmaceutical, Research, Therapy, Acquisition, Pfizer, Roche, Cardiology, Food, Neurology, Reata Pharmaceuticals, Portola Pharmaceuticals, European Medicines Agency, Sickle cell disease, Disease, Actelion, Orthostatic hypertension, AIDE, Biology, Development, Biogen, Pharmaceutical industry

“We are pleased to welcome a proven clinical development leader of Dr. Rajiv Patni’s caliber to our Board of Directors,” said David Lamond, chairperson of Quince’s Board of Directors.

Key Points: 
  • “We are pleased to welcome a proven clinical development leader of Dr. Rajiv Patni’s caliber to our Board of Directors,” said David Lamond, chairperson of Quince’s Board of Directors.
  • Most recently, he served as Chief Research and Development Officer at Reata Pharmaceuticals, a commercial-stage company recently acquired by Biogen.
  • Previously, Dr. Patni also served as Chief Medical Officer at several successful public, small-cap, and commercial-stage biopharmaceutical companies – Global Blood Therapeutics, Portola Pharmaceuticals, and Adamas Pharmaceuticals.
  • Earlier in his career, Dr. Patni held roles of increasing responsibility at Pfizer, Roche, and Actelion.

Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia

Retrieved on: 
Monday, February 12, 2024
Master of Science, Diabetes, European Commission, Paratriathlon, FARA, Headache, Research, Movement disorder, BIIB, Diarrhea, Spasm, Drug development, Nausea, Vomiting, Back pain, Biogen, European, Safety, Hearing loss, Civil service commission, Ataxia, Part Two, Fatigue, Life expectancy, European Medicines Agency, Muscle weakness, Patient, Optimism, Medulla oblongata, Clinical trial, Speech, Ageing, Scoliosis, Appetite, FA, Pharmaceutical industry

“Friedreich’s ataxia patients treated with SKYCLARYS in the clinical trial experienced important and clinically meaningful improvements for their daily lives.

Key Points: 
  • “Friedreich’s ataxia patients treated with SKYCLARYS in the clinical trial experienced important and clinically meaningful improvements for their daily lives.
  • At the end of the 48-week study, patients who received SKYCLARYS had significantly improved modified Friedreich Ataxia Rating Scale (mFARS) scores relative to placebo.
  • Biogen is committed to working closely with all stakeholders to ensure that eligible European patients can have access to this treatment.
  • SKYCLARYS is also approved for use in the United States, and Biogen is engaging with regulatory authorities in other regions.

Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast 2024-2034: Market By Drug Class; By Indication; By Distribution Channel; and By Region - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 8, 2024
Pharmaceutical, Health, Mental Health, Internet, Anxiety, DSM-IV codes, SAD, MDD, Research, PureTech Health, USD, Pharmacy, Social anxiety disorder, Prevalence, Patient, Distribution, GAD, PH94B, Ulotaront, FDA, Disorder, Tic disorder, PPD, Market, Depression, AbbVie, Zuranolone, MOA, Food, Commercialization, Therapy, TAAR1, Major depressive disorder, Sunovion, ADAA, Postpartum depression, NDA, Biogen, Conference, Pharmaceutical industry

The "Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast 2024-2034: Market By Drug Class; By Indication; By Distribution Channel; and By Region" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast 2024-2034: Market By Drug Class; By Indication; By Distribution Channel; and By Region" report has been added to ResearchAndMarkets.com's offering.
  • The global anxiety disorders and depression treatment market size was estimated to be USD 21.56 billion in 2023 and is expected to reach at USD 41.83 billion by 2034 with a CAGR of 6.21% during the forecast period 2024-2034.
  • Rising research & development activities for the development of innovative drugs for the treatment of anxiety & depression disorders is predicted to boost the market growth during the forecast period.
  • This application pertains to the use of cariprazine as an add-on treatment for individuals with major depressive disorder (MDD) who are already undergoing antidepressant therapy.

Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors

Retrieved on: 
Thursday, February 8, 2024
Standard of care, Immunotherapy, Amgen, Prostate cancer, Research, SITC, Society, Patient, ESSA, FDA, Publication, Biomarker, Doctor of Philosophy, NanoString Technologies, Therapy, Drug development, Biogen, Journal, University, Puma Biotechnology

Dr. Cesano succeeds Dr. Kenneth Hillan, who will step down effective today after a successful 7-year tenure as a director of Zymeworks.

Key Points: 
  • Dr. Cesano succeeds Dr. Kenneth Hillan, who will step down effective today after a successful 7-year tenure as a director of Zymeworks.
  • “Zymeworks is honored to welcome Dr. Cesano to our board of directors,” said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks.
  • She joins three other new directors appointed in 2023: Mr. Derek Miller, Mr. Carlos Campoy, and Dr. Nancy Davidson.”
    “The Zymeworks board of directors is sincerely grateful to Dr. Hillan for his dedicated service and significant contributions to the board.
  • Dr. Cesano was also appointed to serve as a member of the research and development committee and nominating and corporate governance committee of the board of directors.

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

Retrieved on: 
Wednesday, February 7, 2024
Rule, Therapy, Biogen

CAMBRIDGE, Mass., Feb. 7, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule") for continued listing.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 7, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule") for continued listing.
  • To regain compliance with the Rule, the Company's ordinary shares were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, which was achieved on February 6, 2024.
  • Therefore, the Nasdaq Listing Qualifications Staff considers the prior bid price deficiency matter now closed.
  • NeuroSense's CEO, Alon Ben-Noon said, "Regaining compliance with the Nasdaq minimum bid price listing requirement is an important event as we continue to focus on the advancement of PrimeC following the recently announced positive top-line results from the Phase 2b PARADIGM trial.

Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments

Retrieved on: 
Monday, February 5, 2024
ACT, Cardiomyopathy, Duchenne muscular dystrophy, Pfizer, LMNA, MD, FDA, Andexanet alfa, Georgetown University Law Center, Mount Sinai School, ATTR, Senior advisor, International Society, Private practice, UCSD, Alexion, Law, Rare disease, Georgetown Journal, Nephrology, Neurology, Civil Service (United Kingdom), Biogen, University, Development, American Heart Association, Hospital, Orthostatic hypertension, Bachelor, Reata Pharmaceuticals, International law, Professor, Disclosure, Information technology, EMA, Southern Illinois University, Therapy, Assistant, Pediatrics, Sickle cell disease, Pharmaceutical industry

“The accumulating talent bench at Lexeo has overseen some of the most transformative clinical development programs, drug approvals and product launches in rare disease and precision cardiovascular medicine,” said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics.

Key Points: 
  • “The accumulating talent bench at Lexeo has overseen some of the most transformative clinical development programs, drug approvals and product launches in rare disease and precision cardiovascular medicine,” said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics.
  • During her tenure, Dr. See Tai led the late-stage clinical development program of tafamidis for ATTR cardiomyopathy (ATTR-ACT), which achieved global regulatory approvals, and the Phase 3 LMNA dilated cardiomyopathy clinical program.
  • In addition to late-stage clinical development, Dr. See Tai was responsible for strategic clinical planning for early-stage development candidates such as those for other genetic cardiomyopathies and Duchenne Muscular Dystrophy.
  • Dr. Adler’s work has led to the development of a novel cardiovascular gene therapy candidate entering late-stage clinical development.

Alkeus Pharmaceuticals Appoints Seemi Khan, M.D., Chief Medical Officer

Retrieved on: 
Tuesday, January 23, 2024
Assistant, Patient, Paratriathlon, Quark Pharmaceuticals, Biogen, Reata Pharmaceuticals, Stargardt disease, Public health, Acquisition, Disease, Brandeis University, Harvard University, AbbVie, Rheumatology, Pharmaceutical industry

CAMBRIDGE, Mass., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc. today announced that Seemi Khan, M.D., M.P.H., M.B.A., has joined the Company as Chief Medical Officer.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc. today announced that Seemi Khan, M.D., M.P.H., M.B.A., has joined the Company as Chief Medical Officer.
  • “We are thrilled to welcome Dr. Khan to the Alkeus executive team as we pursue our mission to innovate transformative therapies for degenerative eye diseases,” said Leonide Saad, Ph.D., President and CEO at Alkeus.
  • “An accomplished executive, Dr. Khan has a track record in bringing rare disease treatments to patients in need across multiple therapeutic areas.”
    Prior to joining Alkeus, Dr. Khan served as Chief Medical Officer at Reata Pharmaceuticals through its acquisition by Biogen, where she oversaw all clinical programs from early stage to commercialization.
  • My commitment to medical innovation and patient care aligns seamlessly with Alkeus' mission, and I look forward to driving forward this life-changing treatment."

Muscular Dystrophy Association Opens Registration for Campers and Volunteers for MDA Summer Camp 2024 to be Held at Locations Nationwide

Retrieved on: 
Monday, January 22, 2024
Life, Volunteering, Muscular Dystrophy Association, Harley-Davidson, Community engagement, Muscular dystrophy, Biogen, General Motors, National Association, NALC, Neuromuscular disease, MDA, Creativity, Magic, Counselor, Summer camp, Tourism

New York, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today the opening of registration for both campers and volunteers for its MDA Summer Camp program.

Key Points: 
  • New York, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today the opening of registration for both campers and volunteers for its MDA Summer Camp program.
  • MDA Summer Camp serves children and young adults ages 8 to 17 living with muscular dystrophy and related neuromuscular diseases.
  • Last summer, more than 800 campers attended MDA Summer Camp, with nearly 600 volunteers.
  • As is the case every year, MDA Summer Camp is offered on a first-come, first-served basis at no cost to participants.

Third Rock Ventures Expands Senior Team with Seasoned Biotech Executives

Retrieved on: 
Thursday, January 25, 2024
Professional Services, Health, Other Health, Other Science, Finance, Science, Biotechnology, Constellation, Bristol Myers Squibb, Vyasa, Philosophy, Biochemistry, Celgene, Patient, Outline of health sciences, Courtney, Therapy, Thought, Flare, Biology, Partnership, Rutgers University, Third Rock Ventures, GSK, University, Biogen, Harvard University, Tulane University, Economics, MBA, AB, Acquisition, Harvard Business School, Harvard College, IPO, Rock Ventures, Purdue University, Psychology, Ewing Marion Kauffman Foundation, Columbia University, Doctor of Philosophy, Jigar, Kearney (consulting firm), Beam Therapeutics

Third Rock Ventures announced today that it has expanded its senior team with the addition and promotion of several industry leaders.

Key Points: 
  • Third Rock Ventures announced today that it has expanded its senior team with the addition and promotion of several industry leaders.
  • Jigar, who joined Third Rock in 2021 as a venture partner, has made significant contributions to the firm’s discovery and company creation activities.
  • Steve Paul, M.D., who has been affiliated with Third Rock since 2010, has re-joined as a venture partner.
  • Prior to Third Rock, Courtney was an early employee and the chief business officer of Beam Therapeutics.

Slingshot Biosciences Announces Election of Nicolas Barthelemy as Executive Chair

Retrieved on: 
Wednesday, January 24, 2024
Health, Other Science, Research, Pharmaceutical, Science, Biotechnology, Engineering, Life Technologies, Patient, Therapy, Senior management, UC, Repligen, University of California, Berkeley, Biogen, Chemical engineering, Growth

Slingshot Biosciences Inc., a leader in the development of cell mimics for cell therapy, diagnostics, and rare disease research, is proud to announce the addition of Nicolas Barthelemy as its Executive Chair.

Key Points: 
  • Slingshot Biosciences Inc., a leader in the development of cell mimics for cell therapy, diagnostics, and rare disease research, is proud to announce the addition of Nicolas Barthelemy as its Executive Chair.
  • “We have been working closely with Nicolas over the last two years and are excited to bring his experience, operational expertise, and strategic insights to bear on this next phase of our growth,” said Dr. Jeffrey Kim - CEO & President of Slingshot Biosciences.
  • Nicolas also currently holds board positions at Repligen, Inc., Biocare Medical, and Nanocellect.
  • With end-applications ranging from Research and Bioprocessing to Hematology, Diagnostics and Therapeutics, we have the opportunity to build a company that could meaningfully impact a very broad area of Life Sciences,” said Nicolas Barthelemy.